within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA14_Dopexamine;

model Dopexamine
  extends Pharmacolibrary.Drugs.ATC.C.C01CA14;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01CA14</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dopexamine is a synthetic catecholamine that acts as a dopamine agonist and β2-adrenoreceptor agonist, used for the treatment of heart failure and low cardiac output states. It enhances cardiac contractility, vasodilation, and renal perfusion. Its clinical use has decreased in recent years due to limited efficacy data and adverse effects; it is not widely approved or in common use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on studies in adult healthy volunteers and critically ill patients. Parameters reported mostly for intravenous infusion.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Benfield, P (1990). Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. <i>Drugs</i> 39(2) 308–330. DOI:<a href=\"https://doi.org/10.2165/00003495-199039020-00009\">10.2165/00003495-199039020-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1970288/\">https://pubmed.ncbi.nlm.nih.gov/1970288</a></p></li><li><p>Perrin, G, et al., &amp; Martin, C (1993). [Dopexamine: a new dopaminergic agonist]. <i>Annales francaises d&#x27;anesthesie et de reanimation</i> 12(3) 308–320. DOI:<a href=\"https://doi.org/10.1016/s0750-7658(05)80658-6\">10.1016/s0750-7658(05)80658-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7902685/\">https://pubmed.ncbi.nlm.nih.gov/7902685</a></p></li><li><p>Birnbaum, J, et al., &amp; Kox, WJ (2003). [The effect of dopexamine and iloprost on plasma disappearance rate of indocyanine green in patients in septic shock]. <i>Der Anaesthesist</i> 52(11) 1014–1019. DOI:<a href=\"https://doi.org/10.1007/s00101-003-0580-1\">10.1007/s00101-003-0580-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14992087/\">https://pubmed.ncbi.nlm.nih.gov/14992087</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dopexamine;
